Reviewing Roka Bioscience (ROKA) and Its Peers

Roka Bioscience (NASDAQ: ROKA) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Roka Bioscience to related companies based on the strength of its profitability, valuation, analyst recommendations, risk, dividends, earnings and institutional ownership.

Valuation & Earnings

This table compares Roka Bioscience and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Roka Bioscience $7.24 million -$30.78 million -0.11
Roka Bioscience Competitors $217.30 million -$39.39 million -69.93

Roka Bioscience’s competitors have higher revenue, but lower earnings than Roka Bioscience. Roka Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Roka Bioscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Roka Bioscience -409.83% -121.16% -68.51%
Roka Bioscience Competitors -3,245.85% -535.71% -39.31%

Institutional and Insider Ownership

48.6% of Roka Bioscience shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 29.2% of Roka Bioscience shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Roka Bioscience and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roka Bioscience 0 0 1 0 3.00
Roka Bioscience Competitors 529 2441 6604 124 2.65

Roka Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 890.10%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.27%. Given Roka Bioscience’s stronger consensus rating and higher possible upside, equities analysts plainly believe Roka Bioscience is more favorable than its competitors.

Volatility & Risk

Roka Bioscience has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Roka Bioscience’s competitors have a beta of 1.58, meaning that their average stock price is 58% more volatile than the S&P 500.

Summary

Roka Bioscience beats its competitors on 9 of the 12 factors compared.

Roka Bioscience Company Profile

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

What are top analysts saying about Roka Bioscience Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Roka Bioscience Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit